World Future
  • Home
  • About
  • ads.txt
Sign in Subscribe

Cancer Study

A collection of 1 post
Debiopharm Explores Potential Of Inhibitor Debio 0123 in Phase 1 Cancer Study
Cancer Study

Debiopharm Explores Potential Of Inhibitor Debio 0123 in Phase 1 Cancer Study

LAUSANNE, Switzerland, Dec. 17, 2021 /PRNewswire/ — Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today the first patient treated in the newly launched open-label, phase I study evaluating Debio 0123, an oral, potent and highly selective WEE1 inhibitor, as monotherapy in patients with advanced solid tumors (NCT05109975). Part of
17 Dec 2021 2 min read
Page 1 of 1
World Future © 2025
  • Sign up
Powered by Ghost